Nuevocor
Clinical-stage A*STAR spin-out developing mechanobiology-centered genetic medicines for cardiomyopathies; lead candidate NVC-001 is an AAV gene therapy for LMNA-related dilated cardiomyopathy, cleared by the FDA IND in 2025 and advancing into a Phase 1/2 trial.
Headquarters
Singapore / Paris, France / Philadelphia, USA
Year Founded
2021
Founders
Yann Chong Tan, Yin Loon Lee, Brian Burke, Colin Stewart, Mark Kay
Country
Singapore
Financial Information
Funding Stage
Series B
Recent Funding
$80.6M
Funding By
Kurma Partners, Angelini Ventures, EDBI, ClavystBio, Boehringer Ingelheim Venture Fund
Core Technology
PrOSIA mechanobiology platform with AAV gene therapy delivery
Product Type
Gene Therapy
Pipeline Stage (Very Important)
Regulatory Status
- IND Filed: Yes
- FDA/EMA Status: FDA IND cleared (2025)
- Clinical Trial Registration: Phase 1/2 NVC-001 in LMNA-related dilated cardiomyopathy (planned)
- Patents / IP Status: Filed (mechanobiology and gene therapy IP from A*STAR and Stanford)
Partnerships
Pharma Collaborations
Boehringer Ingelheim Venture Fund (investor)
Academic / Hospital Tie-ups
A*STAR (spin-out origin), Stanford University
CRO/CDMO Partnerships
None disclosed
Market & Differentiation
Targets the biomechanical cause rather than replacing the gene, aiming for a one-time therapy